Why Side Effect Profiles Matter in Your Treatment Choice
Understanding Wegovy vs Mounjaro Side Effects Profile Differences
The side effects of Wegovy UK versus Mounjaro stem from their distinct mechanisms of action, making this comparison essential for treatment selection. Wegovy (semaglutide) activates GLP-1 receptors exclusively, whilst Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors simultaneously. This dual-action approach may influence the frequency and intensity of gastrointestinal side effects, though both medications share common adverse reactions including nausea, vomiting, and diarrhoea.
Clinical trials demonstrate that the side effects of Wegovy UK typically emerge during dose escalation phases, with most patients experiencing peak symptoms during the first 8-12 weeks of treatment. Mounjaro follows a similar pattern, though its dual receptor mechanism may produce different tolerability experiences in individual patients. Both treatments require careful dose titration to minimise adverse effects whilst maximising therapeutic benefits for weight management.
Wegovy vs Mounjaro Pricing and Side Effect Management Costs
When considering the side effects of Wegovy UK versus Mounjaro, treatment costs play a crucial role in long-term adherence and management strategies. EverydayMeds offers Wegovy starting at £79.99 for the 0.25mg starter dose with new customer code FIRST40 applied at checkout, progressing to £209.99 for the 2.4mg maintenance dose. Our Intro Duo bundle provides both starter doses (0.25mg and 0.5mg) for £169.99, covering your first two months with convenient single delivery.
Mounjaro pricing follows a different structure, reflecting its unique dosing schedule and dual-receptor mechanism. Both treatments require prescription-only medicine oversight through our GPhC #9012878 registered pharmacy, ensuring proper clinical monitoring for side effect management. Returning customers benefit from code DOSE25 applied at checkout, whilst our bundle options provide treatment continuity without repeated ordering during dose escalation phases.
Clinical Evidence for Side Effects of Wegovy UK and Mounjaro
The STEP trial programme, particularly findings published by Wilding et al. in NEJM 2021, documented comprehensive side effect profiles for Wegovy in UK patient populations. Gastrointestinal adverse effects occurred in approximately 84% of participants, with nausea being the most frequently reported side effect during initial treatment phases. Most adverse effects were mild to moderate in severity and decreased over time as patients adapted to treatment.
Mounjaro's SURMOUNT trials revealed similar gastrointestinal side effect patterns, though the dual GLP-1/GIP mechanism may influence individual tolerance profiles differently. Both medications demonstrated acceptable safety profiles when used alongside reduced-calorie diet and increased physical activity, as required by their UK licensing conditions.
How Wegovy's Mechanism Influences Side Effects
Understanding how Wegovy works helps explain why certain side effects of Wegovy UK occur predictably during treatment initiation and dose escalation. Semaglutide mimics the natural GLP-1 hormone, slowing gastric emptying and promoting satiety through hypothalamic appetite centres. This mechanism directly causes the characteristic gastrointestinal effects including nausea, reduced appetite, and altered bowel movements that many patients experience initially. The FlexTouch pen delivery system ensures precise dosing to minimise unnecessary side effect intensity whilst maintaining therapeutic efficacy. Dose escalation from 0.25mg through to 2.4mg maintenance allows gradual adaptation, reducing the severity of adverse effects compared to rapid dose increases.
EverydayMeds Ordering Process for Side Effects Monitoring
Our streamlined ordering process for both Wegovy and Mounjaro includes comprehensive side effect monitoring to ensure your safety throughout treatment. The 3-minute online clinical assessment captures your medical history, current medications, and previous tolerance experiences to help prescribers evaluate your suitability for either treatment option. Prescriber review typically completes within 3 working days (express 24-hour service available), with specific attention paid to contraindications and drug interactions that might increase side effect risks. Once approved, next-day cold-chain delivery ensures medication integrity whilst our ongoing clinical support helps you manage any adverse effects that may occur during treatment. This comprehensive approach ensures both treatments remain safe and effective throughout your weight management journey.
Storage Requirements and Side Effects of Wegovy UK Considerations
Proper storage significantly impacts both efficacy and potential side effects of Wegovy UK, making this comparison with Mounjaro particularly relevant for UK patients. Wegovy maintains stability for up to 6 weeks at room temperature below 30°C once removed from refrigerated storage, compared to Mounjaro's 21-day room temperature limit. This extended stability provides greater flexibility for patients travelling or experiencing temporary storage challenges without compromising medication effectiveness. Degraded medication may cause unpredictable side effects or reduced therapeutic response, making proper storage essential for optimal treatment outcomes. Both medications require refrigeration at 2-8°C before first use and should never be frozen or exposed to direct sunlight.
Dose Escalation and Side Effect Management Strategies
The side effects of Wegovy UK are intrinsically linked to its mandatory dose escalation schedule, starting at 0.25mg and progressing to 2.4mg maintenance over 16 weeks. This gradual increase allows your digestive system to adapt whilst minimising severe gastrointestinal adverse effects that might occur with rapid dose changes. Mounjaro follows a different escalation pattern with six available doses from 2.5mg to 15mg, potentially offering more flexibility in finding your optimal balance between efficacy and tolerability.
Many patients find that initial side effects diminish significantly by weeks 8-12 of treatment, regardless of which medication they choose. Staying hydrated, eating smaller meals, and avoiding high-fat foods can help manage common adverse effects during the adaptation period. Both treatments allow dose reduction if side effects become problematic, though this should always be discussed with your prescribing clinician.
Choosing Between Wegovy and Mounjaro Based on Side Effect Tolerance
Your prescriber will consider multiple factors when recommending between Wegovy and Mounjaro, with side effect tolerance being a primary consideration alongside clinical effectiveness. Both treatments are available through EverydayMeds' comprehensive service, allowing flexible switching if initial tolerance proves challenging. Our clinical team provides ongoing support to help you manage any adverse effects that may occur during treatment, ensuring you receive optimal care regardless of which prescription-only medicine best suits your needs.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
